Safety, tolerability and efficacy of the addition of bevacizumab to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer (mCRC): Results of TREE 2 cohort of the TREE study

被引：0
|
作者：
Hochster, H.
Hart, L.
Ramanathan, R. K.
Hainsworth, J.
Griffing, S.
Mass, R.
Nagarwala, Y.
Jirau-Lucca, G.
Shpilsky, A.
Childs, B. H.
机构：
[1] NYU, Inst Canc, New York, NY USA
[2] Florida Canc Specialist, Ft Myers, FL USA
[3] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA 15260 USA
[4] Sarah Cannon Canc Ctr, Nashville, TN USA
[5] Genentech Inc, San Francisco, CA USA
[6] Sanofi Aventis, Bridgewater, MA USA
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study
    Hochster, Howard S.
    Hart, Lowell L.
    Ramanathan, Ramesh K.
    Childs, Barrett H.
    Hainsworth, John D.
    Cohn, Allen L.
    Wong, Lucas
    Fehrenbacher, Louis
    Abubakr, Yousif
    Saif, M. Wasif
    Schwartzberg, Lee
    Hedrick, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3523 - 3529
  • [2] Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study.
    Hochster, H. S.
    Hart, L. L.
    Ramanathan, R. K.
    Hainsworth, J. D.
    Hedrick, E. E.
    Childs, B. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 148S - 148S
  • [3] Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study (vol 26, pg 3523, 2008)
    Hochster
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) : 4697 - 4697
  • [4] Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies.
    Hochster, HS
    Welles, L
    Hart, L
    Ramanathan, RK
    Hainsworth, J
    Jirau-Lucca, G
    Shpilsky, A
    Griffing, S
    Mass, R
    Emanuel, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 249S - 249S
  • [5] Preliminary results of a randomized study of the safety and tolerability of three oxaliplatin-based regimens as first-line treatment for advanced colorectal cancer (CRC) ("Tree" study).
    Welles, L
    Hochster, H
    Ramanathan, R
    Wong, L
    Hart, L
    Shpilsky, A
    Jirau-Lucca, G
    Emanuel, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 254S - 254S
  • [6] Safety of bevacizumab with fluoropyrimidine-based regimens for first-line teatment of metastatic colorectal cancer
    Tyagi, Preeta
    Chu, Edward
    CLINICAL COLORECTAL CANCER, 2006, 6 (03) : 189 - 191
  • [7] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
  • [8] JAPANESE COHORT STUDY OF FIRST LINE CHEMOTHERAPY (CT) FOR METASTATIC COLORECTAL CANCER (MCRC) CONTAINING FLUOROPYRIMIDINE, OXALIPLATIN AND BEVACIZUMAB: EMERALD STUDY, FIRST REPORT
    Taku, K.
    Ohata, K.
    Yamazaki, K.
    Nishikawa, G.
    Watanabe, M.
    Sato, S.
    Oshima, T.
    Hirano, H.
    Amano, T.
    Ohashi, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 220 - 220
  • [9] EFFICACY AND SAFETY OF CETUXIMAB, OXALIPLATIN AND CAPECITABINE AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF A PHASE II STUDY
    Barroso, S.
    Sanches, E.
    Ferreira, J.
    Passos, M.
    Sa, A.
    Nabico, R.
    SottoMayor, C.
    Santo, Espirito J.
    San-Bento, R.
    ANNALS OF ONCOLOGY, 2009, 20 : 65 - 65
  • [10] Efficacy and safety of cetuximab, oxaliplatin, and capecitabine as first-line therapy for metastatic colorectal cancer (mCRC): Results of a phase II study
    Barroso, S. A.
    Sanches, E.
    Ferreira, M.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sotto-Mayor, C.
    Santo, J. Espirito
    San-Bento, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345